Axa
PTGX icon

Axa’s Protagonist Therapeutics PTGX Stock Holding History

Axa’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,888
Closed -$220K – 1136
2024
Q3 		$220K Buy
+4,888
New +$197K ﹤0.01% 1039
2023
Q3 		– Sell
-11,900
Closed -$329K – 1138
2023
Q2 		$329K Sell
11,900
-74,600
-86% -$1.87M ﹤0.01% 991
2023
Q1 		$1.99M Sell
86,500
-21,200
-20% -$356K 0.01% 768
2022
Q4 		$1.18M Hold
107,700
– – ﹤0.01% 860
2022
Q3 		$908K Buy
+107,700
New +$1.02M ﹤0.01% 877

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Axa's PTGX Position: Q4 2024 in Review

Axa sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 4,888 shares — an estimated $220K sold.

Axa first reported a position in PTGX in Q3 2022 and held it in 5 quarters. The position peaked at $1.99M in Q1 2023. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Axa reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Axa sold 4,888 Protagonist Therapeutics shares in Q4 2024, an estimated $220K.
  • Axa first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 5 quarters.
  • Axa's Protagonist Therapeutics position peaked at $1.99M in Q1 2023.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Axa's 13F filing for Q4 2024, filed 14 Feb 2025.